Ind-Swift Laboratories Gains 16.20%: 5 Key Factors Driving the Surge

2 February 2026: Opening Week with Technical Momentum Shift

Ind-Swift Laboratories Ltd began the week at Rs.108.50, down 4.27% from the previous close, reflecting initial volatility. The Sensex also declined by 1.03% to 35,814.09. Despite the weak start, the stock’s technical indicators began signalling a shift from sideways to mildly bullish momentum, supported by positive MACD and KST readings on weekly and monthly charts. However, daily moving averages remained mildly bearish, indicating short-term resistance.

3 February 2026: Mixed Technical Signals Amid Market Recovery

The stock rebounded strongly to close at Rs.113.40, gaining 4.52%, outperforming the Sensex’s 2.63% rise to 36,755.96. Technical momentum remained complex, with bullish MACD and KST contrasting against bearish daily moving averages and neutral RSI. This divergence suggested cautious optimism, with the stock trading below its 52-week high but showing signs of recovery from its 52-week low of Rs.67.15.

4 February 2026: Sideways Trend with Divergent Indicator Signals

Ind-Swift Laboratories continued its upward trajectory, closing at Rs.119.45 (+5.34%), while the Sensex gained a modest 0.37% to 36,890.21. Despite the price rally, technical momentum shifted from mildly bullish to sideways, reflecting mixed signals. The MACD remained bullish, but the RSI turned bearish on weekly and monthly charts, indicating potential overbought conditions easing. Daily moving averages turned mildly bearish, and volume trends lacked confirmation, suggesting consolidation ahead.

5 February 2026: New 52-Week High and Golden Cross Signal Bullish Breakout

The stock surged to a new 52-week high of Rs.124.60, closing at Rs.122.40 (+2.47%), despite the Sensex declining 0.53% to 36,695.11. This day marked a pivotal technical event with the formation of a Golden Cross, where the 50-day moving average crossed above the 200-day moving average, signalling a potential sustained upward trend. The stock traded above all key moving averages, reinforcing strong momentum. The Mojo Score remained at 34.0 with a Sell grade, upgraded from Strong Sell, reflecting cautious optimism amid the rally.

6 February 2026: Continued Rally, New 52-Week High, and Mojo Upgrade

Ind-Swift Laboratories extended its gains, hitting a new 52-week high of Rs.128.60 and closing at Rs.131.70 (+7.60%), vastly outperforming the Sensex’s 0.10% gain to 36,730.20. The stock’s four-day cumulative return reached 14.65%, supported by bullish technical indicators including positive MACD, Bollinger Bands, and KST across weekly and monthly charts. The Mojo Grade was upgraded to Hold with a score of 51.0, reflecting improved financial performance and technical momentum. The stock’s market cap grade remained at 4, indicating a mid-tier valuation within its sector.

Key Takeaways from the Week

Strong Outperformance: Ind-Swift Laboratories Ltd outpaced the Sensex by a wide margin, gaining 16.20% versus the benchmark’s 1.51%, driven by sustained buying interest and technical breakthroughs.

Technical Momentum Shift: The formation of a Golden Cross and bullish MACD and KST indicators on weekly and monthly charts signalled a positive medium- to long-term trend shift, despite some short-term RSI caution.

New 52-Week Highs: The stock set new highs on 5 and 6 February, reaching Rs.124.60 and Rs.128.60 respectively, reflecting strong price momentum and investor confidence.

Mojo Grade Upgrade: The upgrade from Sell to Hold with a Mojo Score of 51.0 on 5 February highlights improved financial results and technical strength, although valuation and fundamental challenges remain.

Volume and Market Cap: The stock’s volume surged notably on 6 February, supporting the price rally. Its market cap grade of 4 places it in the mid-tier range within the Pharmaceuticals & Biotechnology sector.

Conclusion: A Week Marked by Technical Breakthroughs and Upgraded Outlook

Ind-Swift Laboratories Ltd’s performance over the week ending 6 February 2026 was characterised by a decisive shift in technical momentum, culminating in new 52-week highs and a significant Mojo Grade upgrade. The stock’s 16.20% gain dwarfed the Sensex’s modest 1.51% rise, underscoring its strong relative strength within the Pharmaceuticals & Biotechnology sector.

The Golden Cross formation and bullish MACD and KST indicators provide a solid foundation for sustained upward momentum, although short-term caution is advised given mixed RSI signals and the absence of strong volume confirmation in earlier sessions. The upgrade to a Hold rating reflects improved financial results, including a 115.61% increase in net sales over six months and a 371.8% surge in quarterly profit after tax, signalling operational improvements.

Investors should monitor the stock’s ability to maintain levels above recent highs and watch for volume trends that confirm the durability of this rally. While valuation risks and fundamental challenges remain, the current technical and financial landscape positions Ind-Swift Laboratories Ltd as a noteworthy performer in a cautious market environment.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →